138 related articles for article (PubMed ID: 10190732)
21. Alpha 1-blocking properties of carvedilol during acute and chronic administration.
Giannattasio C; Cattaneo BM; Seravalle G; Carugo S; Mangoni AA; Grassi G; Zanchetti A; Mancia G
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S18-22. PubMed ID: 1378144
[TBL] [Abstract][Full Text] [Related]
22. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis.
Aguilar-Olivos N; Motola-Kuba M; Candia R; Arrese M; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
Ann Hepatol; 2014; 13(4):420-8. PubMed ID: 24927613
[TBL] [Abstract][Full Text] [Related]
23. After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis?
Wani ZA; Baht RA; Bhadoria AS; Maiwall R; Majeed Y; Khan AA; Zargar SA; Shah MA; Khan KM
Saudi J Gastroenterol; 2015; 21(5):278-83. PubMed ID: 26458853
[TBL] [Abstract][Full Text] [Related]
24. [CLINICAL EFFICACY OF THE RECEPTOR BETA AND ALPHA BLOCKERS - CARVEDILOL AND ORNITHINE-ASPARTATE IN PATIENTS WITH CHD AND CHF COMBINED WITH ALCOHOLIC LIVER DISEASE].
Evdokimova AG; Tomova AV; Tereshchenko OI; Zhukolenko LV; Evdokimov VV
Eksp Klin Gastroenterol; 2016; (6):42-7. PubMed ID: 30280552
[TBL] [Abstract][Full Text] [Related]
25. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
Silkauskaitė V; Kupčinskas J; Pranculis A; Jonaitis L; Petrenkienė V; Kupčinskas L
Medicina (Kaunas); 2013; 49(11):467-73. PubMed ID: 24823927
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.
Krämer BK; Ress KM; Erley CM; Risler T
Eur J Clin Pharmacol; 1992; 43(1):85-8. PubMed ID: 1505616
[TBL] [Abstract][Full Text] [Related]
27. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach.
Stienen U; Meyer-Sabellek W
Clin Investig; 1992; 70 Suppl 1():S65-72. PubMed ID: 1350487
[TBL] [Abstract][Full Text] [Related]
28. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
Lund-Johansen P; Omvik P; Nordrehaug JE; White W
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
[TBL] [Abstract][Full Text] [Related]
29. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension.
Sekiyama T; Komeichi H; Nagano T; Ohsuga M; Terada H; Katsuta Y; Satomura K; Aramaki T
Arzneimittelforschung; 1997 Apr; 47(4):353-5. PubMed ID: 9150854
[TBL] [Abstract][Full Text] [Related]
30. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.
Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC
J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395
[TBL] [Abstract][Full Text] [Related]
31. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
32. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Li T; Ke W; Sun P; Chen X; Belgaumkar A; Huang Y; Xian W; Li J; Zheng Q
BMJ Open; 2016 May; 6(5):e010902. PubMed ID: 27147389
[TBL] [Abstract][Full Text] [Related]
33. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Kim SG; Kim TY; Sohn JH; Um SH; Seo YS; Baik SK; Kim MY; Jang JY; Jeong SW; Lee B; Kim YS; Suk KT; Kim DJ
Am J Gastroenterol; 2016 Nov; 111(11):1582-1590. PubMed ID: 27575713
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial.
Basu S; Senior R; Raval U; van der Does R; Bruckner T; Lahiri A
Circulation; 1997 Jul; 96(1):183-91. PubMed ID: 9236433
[TBL] [Abstract][Full Text] [Related]
35. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation.
Merkel C; Bolognesi M; Sacerdoti D; Bombonato G; Cavasin L; Gatta A
Aliment Pharmacol Ther; 2005 Sep; 22(5):433-9. PubMed ID: 16128681
[TBL] [Abstract][Full Text] [Related]
36. Vasodilating beta-blockers in heart failure.
Raftery EB
Eur Heart J; 1995 Jul; 16 Suppl F():32-7. PubMed ID: 8521882
[TBL] [Abstract][Full Text] [Related]
37. Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise.
Omvik P; Lund-Johansen P; Myking O
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S90-6. PubMed ID: 1378157
[TBL] [Abstract][Full Text] [Related]
38. Influences of carvedilol treatment on the effects of acetylcholine on regional haemodynamics in the spontaneously hypertensive rat.
Granstam SO; Fellström B; Lind L
Clin Sci (Lond); 1998 Sep; 95(3):303-9. PubMed ID: 9730849
[TBL] [Abstract][Full Text] [Related]
39. [Neither propranolol nor the vasodilating beta-blocker carvedilol have a direct effect on coronary resistance vessels].
Sievert H; Schmidt T; Frey G; Schräder R; van der Does R; Kaltenbach M; Kober G
Z Kardiol; 1991 Jan; 80(1):15-9. PubMed ID: 1674632
[TBL] [Abstract][Full Text] [Related]
40. Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.
Omvik P; Lund-Johansen P
Eur Heart J; 1991 Jun; 12(6):736-40. PubMed ID: 1860471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
